| scholarly article | Q13442814 |
| P2093 | author name string | Yong Liao | |
| P2860 | cites work | Immunotherapy for hepatocellular carcinoma | Q26775188 |
| Hepatitis B and Hepatitis C Reactivation in the Biologic Era | Q26781993 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Systemic therapy for advanced hepatocellular carcinoma: an update | Q33593213 | ||
| Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. | Q33872964 | ||
| Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter. | Q33960740 | ||
| NAFLD, NASH and liver cancer | Q34374372 | ||
| The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 | Q34533596 | ||
| Cancer immunotherapy targeting neoantigens | Q36889067 | ||
| The global burden of liver disease: the major impact of China | Q36901892 | ||
| Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. | Q37021822 | ||
| Fulminant Myocarditis with Combination Immune Checkpoint Blockade | Q37595462 | ||
| Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. | Q37756309 | ||
| Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. | Q38321507 | ||
| The yin and yang of evasion and immune activation in HCC. | Q38367030 | ||
| Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs | Q38446397 | ||
| Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma | Q38492092 | ||
| Should Patients With NAFLD/NASH Be Surveyed for HCC? | Q90774408 | ||
| Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges | Q90833246 | ||
| Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment | Q90857597 | ||
| Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions | Q91048937 | ||
| [Report of cancer epidemiology in China, 2015] | Q91205401 | ||
| HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation | Q91282897 | ||
| From NASH to HCC: current concepts and future challenges | Q91557675 | ||
| Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma | Q91987072 | ||
| Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China | Q92620201 | ||
| Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics | Q38566445 | ||
| Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease | Q38627907 | ||
| The biology of Hepatocellular carcinoma: implications for genomic and immune therapies | Q38635474 | ||
| The current status and future directions of hepatitis B antiviral drug discovery | Q38802098 | ||
| Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure | Q38809542 | ||
| The role of innate immunity in the immunopathology and treatment of HBV infection | Q38809549 | ||
| Adaptive immunity in HBV infection | Q38809554 | ||
| Mechanisms of HBV-induced hepatocellular carcinoma. | Q38809557 | ||
| Cancer treatment and survivorship statistics, 2016. | Q38859236 | ||
| Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies | Q38945576 | ||
| China's efforts to shed its title of "Leader in liver disease". | Q39329734 | ||
| Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. | Q39388862 | ||
| Cancer statistics in China, 2015. | Q40064386 | ||
| Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas | Q40146079 | ||
| Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | Q40548309 | ||
| Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager | Q41592942 | ||
| Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial | Q41748360 | ||
| A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma. | Q41928187 | ||
| Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area | Q42249970 | ||
| Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b | Q46514441 | ||
| Toll-Like Receptor 7 Agonist GS-9620 Induces Prolonged Inhibition of HBV via a Type I Interferon-Dependent Mechanism | Q47564810 | ||
| Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy | Q47597987 | ||
| Precision diagnosis and treatment of liver cancer in China | Q47606782 | ||
| Chemotherapy for hepatocellular carcinoma: current status and future perspectives | Q47775953 | ||
| Personalized cancer vaccines: Targeting the cancer mutanome | Q49956120 | ||
| Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma | Q50022186 | ||
| Roles of alcohol consumption in fatty liver: a longitudinal study. | Q51006476 | ||
| Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. | Q52620810 | ||
| Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. | Q53922343 | ||
| Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. | Q54977952 | ||
| Immune checkpoint therapy in liver cancer. | Q55008806 | ||
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | Q56830540 | ||
| Recent developments with immunotherapy for hepatocellular carcinoma | Q56890617 | ||
| Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections | Q57178052 | ||
| Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma | Q57486613 | ||
| Perspectives and limitations for nucleo(t)side analogs in future HBV therapies | Q59360792 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Immunotherapy for hepatocellular carcinoma: current status and future perspectives | Q60960900 | ||
| Liver cancer incidence and mortality in China: Temporal trends and projections to 2030 | Q61454143 | ||
| Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China | Q64069876 | ||
| Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action | Q64124545 | ||
| Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern | Q64244916 | ||
| Precision oncology in liver cancer. | Q64905840 | ||
| The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. | Q64910653 | ||
| Cancer Immunoediting by Innate Lymphoid Cells. | Q64913309 | ||
| Regional immunity in tissue homeostasis and diseases | Q88923519 | ||
| P433 | issue | 3 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 291-298 | |
| P577 | publication date | 2020-01-10 | |
| P1476 | title | Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma | |
| P478 | volume | 7 |
Search more.